Efavirenz Patent Expiration
Efavirenz is used for managing HIV infection in combination with other antiviral drugs. It was first introduced by Bristol Myers Squibb Co
Efavirenz Patents
Given below is the list of patents protecting Efavirenz, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sustiva |
US6238695 (Pediatric) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Oct 06, 2019
(Expired) | Bristol Myers Squibb |
| Sustiva |
US6555133 (Pediatric) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Oct 06, 2019
(Expired) | Bristol Myers Squibb |
| Sustiva | US6238695 | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Apr 06, 2019
(Expired) | Bristol Myers Squibb |
| Sustiva | US6555133 | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Apr 06, 2019
(Expired) | Bristol Myers Squibb |
| Sustiva |
US6639071 (Pediatric) | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Aug 14, 2018
(Expired) | Bristol Myers Squibb |
| Sustiva |
US6939964 (Pediatric) | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Jul 20, 2018
(Expired) | Bristol Myers Squibb |
| Sustiva | US6639071 | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Feb 14, 2018
(Expired) | Bristol Myers Squibb |
| Sustiva | US6939964 | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Jan 20, 2018
(Expired) | Bristol Myers Squibb |
| Sustiva |
US5663169 (Pediatric) | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Mar 02, 2015
(Expired) | Bristol Myers Squibb |
| Sustiva | US5663169 | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Sep 02, 2014
(Expired) | Bristol Myers Squibb |
| Sustiva |
US5519021 (Pediatric) | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Nov 21, 2013
(Expired) | Bristol Myers Squibb |
| Sustiva | US5519021 | Benzoxazinones as inhibitors of HIV reverse transcriptase |
May 21, 2013
(Expired) | Bristol Myers Squibb |
| Sustiva | US5811423 | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Aug 07, 2012
(Expired) | Bristol Myers Squibb |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Efavirenz's patents.
Latest Legal Activities on Efavirenz's Patents
Given below is the list recent legal activities going on the following patents of Efavirenz.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical
| 29 Apr, 2003 | US6555133 |
| Recordation of Patent Grant Mailed Critical
| 29 Apr, 2003 | US6555133 |
| Issue Notification Mailed Critical
| 10 Apr, 2003 | US6555133 |
| Receipt into Pubs | 14 Mar, 2003 | US6555133 |
| Receipt into Pubs | 06 Mar, 2003 | US6555133 |
| Receipt into Pubs | 03 Mar, 2003 | US6555133 |
| Application Is Considered Ready for Issue Critical
| 28 Feb, 2003 | US6555133 |
| Issue Fee Payment Received Critical
| 19 Feb, 2003 | US6555133 |
| Issue Fee Payment Verified Critical
| 19 Feb, 2003 | US6555133 |
| Receipt into Pubs | 11 Feb, 2003 | US6555133 |
Efavirenz's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Efavirenz:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
